Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Listen to our conference call with Outlook Therapeutics management to learn more about the pivotal data.



November 29, 2021
Outlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter’s Option to Purchase Additional Shares
November 23, 2021 Outlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 Million

Outlook Therapeutics…

…is a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and branch retinal vein occlusion (BRVO).


ONS-5010/ LYTENAVA™ (bevacizumab-vikg) is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet AMD and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (or mAb) that inhibits VEGF and associated angiogenic activity.

ONS-5010 has completed the pivotal clinical trial in our Phase 3 program for wet AMD and is expected to be submitted with the FDA as a new BLA for this ophthalmic indication in the first calendar quarter of 2022. Outlook Therapeutics also intends to commence additional clinical trials for ONS-5010 in DME and BRVO.

If approved, ONS-5010 will be the first and only FDA-approved ophthalmic formulation of bevacizumab to treat retinal diseases.